Amgen Stock Direction Hinges on Bone Cancer Data
LOS ANGELES, Oct 7 (Reuters) - Amgen Inc (AMGN.O) investors stand to reap significant benefits should upcoming data for the biotechnology company's drug denosumab show the medicine can prevent cancer from spreading to the bone.